Celgene Corp (CELG) 95.09 $CELG
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
Final Glance: Biotechnology companies
AP - Tue Sep 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue Sep 02, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Early Glance: Biotechnology companies
AP - Tue Sep 02, 9:57AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene Shares Up 29.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Tue Sep 02, 9:22AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.93. In approximately 4 months, Celgene has returned 29.53% as of today's recent price of $95.77.
Next Resistance Level for Celgene (CELG) is $95.89
Comtex SmarTrend(R) - Tue Sep 02, 9:03AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $94.86 and have already reached the first level of resistance at $95.45. Analysts will be watching for a cross of the next upside pivot targets of $95.89 and $96.92.
Celgene (CELG) On Momo Momentum Watch Today
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
VentiRx Pharmaceuticals Provides Corporate and Clinical Update
PR Newswire - Tue Sep 02, 7:00AM CDT
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at the company including management structure, commitment for future funding, ongoing clinical trials and future clinical development efforts.
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:30PM CDT
Regeneron (REGN) expects adjusted SG&A costs to rise further in the remaining quarters of 2014.
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
Celgene rose 2.4%
at Investor's Business Daily - Tue Aug 26, 5:45PM CDT
Celgene (CELG) rose 2.4% to 95.66 as an Deutsche Bank analyst said upcoming clinical trial data on a Crohn's disease drug could lift shares. The analyst also touted Gilead Sciences (GILD), which fell 1.1% but is still up 16% in Aug.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
Final Glance: Biotechnology companies
AP - Tue Sep 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue Sep 02, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Early Glance: Biotechnology companies
AP - Tue Sep 02, 9:57AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene Shares Up 29.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Tue Sep 02, 9:22AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.93. In approximately 4 months, Celgene has returned 29.53% as of today's recent price of $95.77.
Next Resistance Level for Celgene (CELG) is $95.89
Comtex SmarTrend(R) - Tue Sep 02, 9:03AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $94.86 and have already reached the first level of resistance at $95.45. Analysts will be watching for a cross of the next upside pivot targets of $95.89 and $96.92.
Celgene (CELG) On Momo Momentum Watch Today
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
VentiRx Pharmaceuticals Provides Corporate and Clinical Update
PR Newswire - Tue Sep 02, 7:00AM CDT
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at the company including management structure, commitment for future funding, ongoing clinical trials and future clinical development efforts.
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:30PM CDT
Regeneron (REGN) expects adjusted SG&A costs to rise further in the remaining quarters of 2014.
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
Celgene rose 2.4%
at Investor's Business Daily - Tue Aug 26, 5:45PM CDT
Celgene (CELG) rose 2.4% to 95.66 as an Deutsche Bank analyst said upcoming clinical trial data on a Crohn's disease drug could lift shares. The analyst also touted Gilead Sciences (GILD), which fell 1.1% but is still up 16% in Aug.
